Progenics Pharmaceuticals — Investor Presentation (January 2018)
31 slides from Progenics Pharmaceuticals's investor presentation, Jan 8, 2018
Slide 1: Leading Development of Targeted Radiopharmaceuticals to Detect and Treat Cancer
Leading Development of Targeted Radiopharmaceuticals to Detect and Treat Cancer +, Si C . Exhibit 99.1 FIND FIGHT AND FOLLOW™ Progenics
Slide 2: Disclosure Notice
DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future events. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties inc
Slide 3: Our Mission
OUR MISSION FIND FIGHT AND FOLLOW™ Leading Development of Targeted Radiopharmaceuticals to Detect and Treat Cancer AZEDRA® for Ultra Orphan NETs Near-term commercial opportunity; PDUFA Target Action Date of April 30, 2018 PSMA-Targeted Portfolio for Prostate Cancer Imaging agents and therapeutics de
Slide 4: Pipeline
PIPELINE Sa ED=D> Dx ULTRA-ORPHAN THERANOSTIC AZEDRA® Theranostic Pheochromocytoma & Paraganglioma PDUFA: April PROSTATE CANCER THERANOSTICS 1404 PSMA-targeted SPECT Imaging Agent PyL PsMActargeted PET Imaging Agent 1095 ‘Small Molecule Therapeutic PSMA-TTC ‘Thorium Conjugate Therapeutic DIGITAL TEC
Slide 5: AZEDRA (iobenguane I 131)
% }- +4 AZEDRA’ (iobenguane | 131) > Progenics FIND FIGHT AND FOLLOW™ ae
Slide 6: AZEDRA (iobenguane I 131)
AZEDRA’ (iobenguane | 131) * Selectively targets pheochromocytoma and paraganglioma (Pheo/Para) via the norepinephrine transporter? * Provides powerful and sustained tumor ablation over time * Contains over 99% active, therapeutic |-131 MIBGt * Orphan Drug Designation, Fast Track Status, Breakthroug
Slide 7: Pheochromocytoma and Paraganglioma
PHEOCHROMOCYTOMA AND PARAGANGLIOMA * Rare tumors found primarily in the adrenal glands Results in the release of excess hormones that control heart rate, metabolism and blood pressure Left untreated, tumors most often lead PARA to death due to metastatic disease, high blood pressure, heart failure,
Slide 8: Pheochromocytoma and Paraganglioma
PHEOCHROMOCYTOMA AND PARAGANGLIOMA Annual incidence: 2 to 8 per million in the US 15%-35% 16% ; of cases are metastatic/malignant Of cases suitable for surgery and not eligible recur after initial surgery? T for surgery?? i 4 i ! ' Tumor progression is Usually 5-15 years after initial the leading ca
Slide 9: AZEDRA: Positive Data from Registrational Trial
AZEDRA’*: POSITIVE DATA FROM REGISTRATIONAL TRIAL «et certer study undersea agreement with FDA + 68 evaluable patents Achieved Primary Favorable Tumor Meaningful Impact Safe & Generally Endpoint Response Data on Overall Survival Well Tolerated + 17 patients reported * 92.2% of patients * Data sugges
Slide 10: AZEDRA: Trial Achieved Primary Endpoint
AZEDRA: TRIAL ACHIEVED PRIMARY ENDPOINT Met the primary endpoint evaluating the proportion of patients who achieved a >50% reduction of all antihypertensive medication for at least six months. Under the study protocol, the primary endpoint is achieved if the lower limit of the two-sided 95% confiden
Slide 11: AZEDRA: Favorable Tumor Response Rates
AZEDRA: FAVORABLE TUMOR RESPONSE RATES Key secondary endpoint: the proportion of patients with overall tumor response as measured by RECIST 92.2% of evaluable patients (59/64) who received at least one AZEDRA therapeutic dose achieved partial response or stable disease Proportion of study patients w
Slide 12: AZEDRA: U.S. Market Accessible with Small, Dedicated Salesforce
AZEDRA: U.S. MARKET ACCESSIBLE WITH SMALL, DEDICATED SALESFORCE AZEDRA Initial Sales Territories * Guidelines recommend referral to multi-disciplinary centers with specialized resources * Majority of patients are treated at 20-25 centers, many of which are sites that are participating in our registr
Slide 13: AZEDRA: Approval and Launch Readiness
AZEDRA: APPROVAL AND LAUNCH READINESS Extensive market iw research on Pheo/Para with physicians, patients and caregivers Brand development, . poe Disease awareness positioning and ‘ campaign message research Payer market research of iw value proposition associated with target product pr underway for
Slide 14: AZEDRA: Market Research Insights
AZEDRA: MARKET RESEARCH INSIGHTS * — Recognize the clinical , Identify metastatic/ malignant Pheo/Para as an utility of AZEDRA fromthe | area of high unmet need with two overarching efficacy/safety profile goals of treatment: demonstrated in a heavily | * Reducing symptoms—symptoms related to pre-tr
Slide 15: AZEDRA — Preparing for Commercialization
AZEDRA — PREPARING FOR COMMERCIALIZATION Commercial Launch ..» AZEDRA Service Connection— Patient and HCP services hub ———— e Establish meaningful value proposition and engage payers Build Marketing, Access and Sales team -e Identify and profile Centers of Excellence * AZEDRA - Differentiated and co
Slide 16: Disease Awareness Campaign Launched
DISEASE AWARENESS CAMPAIGN LAUNCHED Jere to Listen, Here to. Patient Conferences HCP + Patient Website: KnowPheoPara.health HCP Conferences Speaker Deck
Slide 17: AZEDRA Summary
AZEDRA® SUMMARY REGULATORY: Exceeded primary end point under special protocol assessment (SPA) PDUFA: April 30, 2018 Orphan Drug designation, Fast Track, Breakthrough Therapy designation, Priority Review No FDA approved therapies, ultra-orphan population that can be targeted with small commercial ef
Slide 18: PSMA Targeted Pipeline
% }- +4 PSMA TARGETED PIPELINE ) FIND FIGHT AND FOLLOW™ Progenics
Slide 19: Addressing Prostate Cancer with a Novel Portfolio of PSMA Targeted Diagnostics and Therapeutics
ADDRESSING PROSTATE CANCER WITH A NOVEL PORTFOLIO OF PSMA TARGETED DIAGNOSTICS AND THERAPEUTICS PSMA CADx Diagnose Treat Monitor Technetium-99m labeled small molecule PSMA-targeted SPECT/CT imaging agent to diagnose and detect localized prostate cancer as well as soft tissue and bone metastases Phas
Slide 20: 1404 PSMA-Targeted Imaging Agent
1404 PSMA-TARGETED IMAGING AGENT * SPECT/CT radiopharmaceutical product candidate targeting PSMA * Phase 3 enrollment complete; data expected 3Q18 * Potential to transform clinical practice with improved detection & monitoring * Initial application: enabling Active Surveillance Gleason 4+5 Lesion SP
Slide 21: 1404 Phase 3 Study Design
1404 PHASE 3 STUDY DESIGN ~450 Biopsy Confirmed Low Grade PC (Gleason Score <3+4) patients SPECT/ CT Prostatectomy Histopathology who are candidates for Imaging or biopsy Active Surveillance Primary Specificity of 1404 to identify patients without clinically significant prostate cancer Endpoint Sens
Slide 22: PyL Imaging Characteristics
Enables visualization of both bone and soft tissue metastases Highly specific to prostate cancer cells, not confounded by degenerative or inflammatory conditions Very high standardized uptake values (SUV) even in small lesions Identified more lesions than conventional imaging Could detect lesions as
Slide 23: PyL Clinical Development Program to Support NDA
PyL CLINICAL DEVELOPMENT PROGRAM TO SUPPORT NDA Indication: PET/CT imaging agent to determine the presence or absence of recurrent and/or metastatic prostate cancer Patient Population Primary End Truth standardto be used Secondary Endpoints Study Status ‘Study 1: PyL Phase 2/3 Trial High risk locali
Slide 24: 1095: PSMA Targeted Small Molecule Theranostic for Prostate Cancer
24 1095: PSMA TARGETED SMALL MOLECULE THERANOSTIC FOR PROSTATE CANCER * Best PSA Response in 25 patients 25 5 10 15 20 PATIENT NUMBER Zechmann et al. Eur J Nuc! Med Mol Imaging, 2014 100 * Targeted small molecule radiotherapeuticthat selectively binds to PSMA * Markedly reduced PSA levelsina heavily
Slide 25: 1095 Phase 2 Study Design
1095 PHASE 1 STUDY DESIGN: Open Label, Dose Escalating, Safety & Efficacy Study 1095 Study Overview: Treatment Screening Treatment Phase unas Fats 2 Follow u| Patients Safety P Dosimetry, Escalation Efficacy Safety Patient Subjects with metastatic castration-resistant prostate cancer (mCRPC) Populat
Slide 26: PSMA-Targeted Thorium Conjugate (PSMA-TTC)
PSMA-TARGETED THORIUM CONJUGATE(PSMA-TTC) Partnered with Bayer 2 6 en) * Ina prostate cancer mouse model, PSMA-TTC proved efficacious to suppress tumor growth and bone degradation! * Phase 1 in patients with mCRPC plannedto commence in 2018 * Potential added effect on bone metastases due to decay pr
Slide 27: Pioneer PSMA CADx
PIONEER PSMA CADx™ PSMA imaging significantly better in PSMA imaging study found a high impact on identifying aggressive tumor in prostate. management intent, with a planned Zamboglou, C. et al, EINMMI 2016 management change in 51% of patients. Roach, PJ. et al, JNM 2017 A patient centric approach t
Slide 28: Corporate Overview
% }- +4 CORPORATE OVERVIEW > Progenics FIND FIGHTAND FOLLOW™
Slide 29: Financial Overview
FINANCIAL OVERVIEW 3Q17 Financial Snapshot * $98.3M cash as of 9/30/17 * Quarterly Revenues: $2.7M * Net loss: $0.22 per share * 70.3M shares outstanding Strong financial position to advance portfolio and launch AZEDRA 2 FIND FIGHTAND FOLLOW™ RELISTOR® franchise provides financial foundation: * Mark
Slide 30: 2018 Program Goals
LEADING DEVELOPMENT OF TARGETED RADIOPHARMACEUTICALS TO DETECT AND TREAT CANCER 2018 Program Goals PDUFA: April 30 AZEDRA® READY TO LAUNCH AT APPROVAL 1404 PyL PSMA-TTC 30 FIND FIGHTAND FOLLOW™
Slide 31: Leading Development of Targeted Radiopharmaceuticals to Detect and Treat Cancer
Leading Development of Targeted Radiopharmaceuticals to Detect and Treat Cancer ~s, Si C . FIND FIGHTAND FOLLOW™ Proge! nics
Progenics Pharmaceuticals — Investor Presentation (January 2018) on 6ix